Results 171 to 180 of about 22,239 (295)

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Therapeutic Potential of Origanum majorana L. Essential Oil in Diabetes Mellitus: Insights From GC–MS Characterization, In Vivo Hypoglycaemic Studies, and In Silico Analyses

Chemistry &Biodiversity, Volume 23, Issue 5, May 2026.
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas, Mohammed Larbi Benamor, Elhafnaoui Lanez, Yahia Bekkar, Lotfi Bourougaa, Ouafa Boudebia, Rania Bouraoui, Aicha Adaika, Nafila Zouaghi, Salah Neghmouche Nacer, Lazhar Bechki, Touhami Lanez, Stefania Garzoli   +12 more
wiley   +1 more source

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes [PDF]

, 2017

core   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1265-1274, May 2026.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. [PDF]

J Dermatol Case Rep, 2014
Attaway A, Mersfelder TL, Vaishnav S, Baker JK.   +3 more
europepmc   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source

Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
Central illustration: Pathophysiological mechanisms linking diabetes mellitus and cardiovascular disease. Chronic hyperglycaemia, insulin resistance, and low‐grade inflammation contribute to endothelial dysfunction, myocardial fibrosis, and cardiomyocyte apoptosis.
Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Paschalis Karakasis, Marios Sagris, Nikias Milaras, Maria Drakopoulou, Andreas Synetos, Ioannis Kyriazis, Ioannis Ioannidis, Costas Tsioufis, Konstantinos Toutouzas   +13 more
wiley   +1 more source

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Ecnoglutide, a once‐weekly GLP‐1 receptor agonist, significantly improves glycaemic control and promotes meaningful weight loss compared with placebo in type 2 diabetes. This systematic review and meta‐analysis of four RCTs demonstrates favourable efficacy with mostly mild gastrointestinal adverse events and no increase in serious safety concerns ...
Mukesh Kumar, Sumet Kumar, Sheikh Muhammad Ebtehaj Ali, Hadia Qazi, Arshia Arif Janjua, Hanzlah Ahmed, Rayan Babar, Rumaisa Imtiaz Sheikh, Laksh Kumar, Sana Mohammad Ali, Fatima Hanif, Khizra Gul, Ayesha Sarwar Ali, Shehzadi Umme Rubab Bukhari, Adarsh Raja, Aayush Chaulagain   +15 more
wiley   +1 more source

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus [PDF]

, 2012

core   +1 more source